Tam CS et al. - The authors analyzed the outcomes of 74 patients diagnosed with BCR-ABL negative myeloproliferative neoplasms (MPN) in blast phase receiving induction chemotherapy (55%), low intensity therapy (16%), stem cell transplantation (SCT; 3%) or supportive care (26%). Responses to chemotherapy can be achieved but are not durable. Long-term survivors had all received SCT either as first therapy or in first remission.
See all
